‘Easter for Eli' 2nd annual cornhole tournament benefits children in hospitals
DUNCANSVILLE, Pa. (WTAJ) — On Sunday, 'Easter for Eli' hosted their second annual cornhole tournament to raise money for gifts baskets that will be delivered to children in the hospital.
The non-profit organization has been delivering baskets to children for 10 years. This will be their 11th.
Easter for Eli was founded in memory of Elias 'Eli' Garrett, a loving 3-year-old boy who lost his battle with Non-Hodgkin's T-cell Lymphoma in 2009. His sister, Kayleigh Garrett, was at the tournament and said it's special to be able to deliver some Easter joy with their dad.
'Just to bring awareness to all of the children that are in the hospital over the Easter holidays, but to their families as well. So I think to be a part of this, and it's bigger than what we are. And so to put the smiles and all those kids' faces really means a lot to me,' Kayleigh said.
Prom event raises money for 2025 African American Heritage Festival in Altoona
Eli's father, Martin, said they've delivered 78,000 Easter baskets and provided $68,000 in gift cards to families.
'We're continuing to grow, continue to share my son's joy and, you know, bring awareness that so many kids are in the hospital over one holiday. We deliver 10,000 baskets, and that's just a drop in the bucket to what's out there,' Martin said.
On Monday, Easter for Eli will start delivering baskets to ensure children receive them in time for the holiday. They plan to start in Pittsburgh and then make stops in Cleveland and Akron.
'It's always a great time to be able to actually go and see the children that we're helping, essentially. You know, we build up year after year. And so to keep this tradition going, it means a lot. And I hope it's around for all the years to come in the future,' Kayleigh said.
April 4 is the last day to donate baskets. If you want to donate, the organization requests that you purchase new items and not place any food in the baskets. You can find the list of donations needed here.
You can also donate online, using PayPal, Venmo, or their Amazon Wishlist.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
a day ago
- USA Today
Are raisins good for you? We asked a dietitian to break down the nutritional benefits.
If you're looking for a snack on the go, a sweet topping to your morning cereal or the star ingredient of an oatmeal raisin cookie, raisins are the versatile dried fruit that you can easily incorporate into a balanced dietary pattern. Raisins are dried grapes, meaning they're naturally quite nutrient-dense. They're high in fiber, and pack a punch with a few essential minerals. We asked an expert to break down everything you need to know about the nutritional benefits of raisins, and how they stack up against grapes. What are raisins good for? Yes, raisins are good for you. They have a similar nutritional profile to other kinds of fruits, says Camila Martin, a registered dietitian nutritionist with UW Health. They are high in carbohydrates and contain a little bit of protein and fat. They're also a relatively good source of iron, magnesium and potassium, says Martin. Raisins are also an excellent source of dietary fiber, says Martin. Over 90% of women and 97% of men don't meet the daily recommended intake of dietary fiber, according to the Dietary Guidelines for Americans 2020-2025. We know that having an adequate amount of dietary fiber is essential for reducing your risk of coronary heart disease and supporting gut health. So, in the context of a balanced dietary pattern, eating raisins could definitely contribute to meeting your daily fiber intake. What's healthier: Grapes or raisins? When comparing grapes and raisins, you might be wondering: Do grapes become less nutritious when they become raisins? There are a few different ways to prepare raisins, from drying them in the sun to using a food dehydrator. During these processes, the water content from the grape is evaporated, and the raisin essentially becomes a super concentrated grape. From a nutritional standpoint, grapes and raisins differ slightly. Raisins are higher in sugar and carbs than grapes are, but they're also a better source of dietary fiber, potassium and iron, per WebMD. So, one isn't necessarily healthier than the other, with pros and cons for each. It ultimately depends on your health goals, says Martin. Raisins are more energy-dense and are better source of fiber, though they also have a higher concentration of sugar. Because grapes have higher water content, they're a snack that'll probably fill you up faster than raisins. Do raisins spike blood sugar? 'There are three major macronutrients that are the building blocks of our food: carbohydrates, fat and protein,' says Martin. Raisins, being a fruit, are primarily made of carbs (which increase your blood sugar). So, consuming raisins may up your blood sugar levels, but because they contain a good amount of dietary fiber, minerals and protein, it should help slow the spike, says Martin. To prevent a potential blood sugar spike, raisins should be consumed in moderation. 'Whenever we're having a snack or meal that's primarily carbohydrates, make sure it's paired with something that has a healthy fat or protein,' says Martin. 'That's going to take away the peaks and valleys that can sometimes show up from foods that contain higher contents of one of those macronutrients.' It's also important to point out that not all sugar is bad. In fact, consuming natural sugars found in whole foods like fruits, vegetables and dairy support essential functions in the body, such as providing energy. A diet rich in fruits, vegetables and whole grains may lower your risk of developing certain chronic diseases, including diabetes and coronary heart disease, per Harvard Health. Ultimately, if you're following a balanced diet in which you are consuming a wide variety of fruits and vegetables, raisins are a great food to add to your weekly rotation.
Yahoo
2 days ago
- Yahoo
Rise in VC activity tees up ‘strong year' for medtech funding: PitchBook
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Increases in venture capital investments have positioned 2025 to be a 'strong year for global medtech funding,' according to a report from market data research firm PitchBook. First quarter VC funding totaled $4.1 billion, the highest it has been since 2022. The number of confirmed transactions hit 216, reversing a four-quarter decline. However, the uptick in medtech mergers and acquisitions that PitchBook predicted under the second Trump administration has yet to emerge, and antitrust regulators are still challenging deals. Medtech VC activity fell in both 2022 and 2023, according to PitchBook. Last year brought signs that the market might be bottoming. The number of VC investments fell for the third year in a row, but the amount of funding was higher than in 2023. Signs of a VC recovery continued into the first quarter of 2025, when the $260 million investment in whole-body-imaging startup Neko Health was the largest of 11 rounds worth $100 million or more. With Elon Musk's brain implant startup Neuralink raising $650 million this month, PitchBook said preliminary data for the second quarter shows more than $3 billion of medtech VC funding so far. VC exits are rare, though. PitchBook said there were no significant medtech VC exits in the first quarter, and the total exit value remained roughly in line with the previous two quarters. Total exit value in recent years has been driven by rare big deals, such as Tempus AI's initial public offering in 2024 and the $6 billion acquisition of Athelas in 2023. PitchBook highlighted three notable exits that closed in the first quarter: Beta Bionics' IPO, Hologics' $350 million takeover of Gynesonics and Boston Scientific's $540 million acquisition of SoniVie. The level of activity has fallen short of PitchBook's expectations. 'Our earlier thesis that the new U.S. presidential administration's more lenient regulatory stance would catalyze M&A activity has yet to play out, as broader market turbulence in early 2025 has complicated dealmaking conditions across sectors,' PitchBook said. 'Additionally, regulatory resistance remains a headwind.' PitchBook cited the Federal Trade Commission's legal challenge to the $627 million private equity buyout of Surmodics as evidence of ongoing regulatory resistance. The FTC challenged the deal on the grounds it 'would lead to a highly concentrated market for outsourced hydrophilic coatings and eliminate significant head-to-head competition.' Recommended Reading Medtech venture investment recovery continues, but startup M&A remains limited: Pitchbook Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech
Shares of CureVac N.V. CVAC have skyrocketed 40.8% in a month after the company signed a definitive agreement to be acquired by BioNTech SE BNTX in an all-stock transaction last week. Per the agreement, each CVAC share will be exchanged for approximately $5.46 worth of BNTX American Depositary Shares (ADS), implying a total equity value of around $1.25 billion for CureVac. The consideration per ADS represents a premium of 55% to CVAC's three-month volume-weighted average price of approximately $3.53 as of June 11, 2025. Subject to the closing of the transaction, CureVac shareholders are expected to own between 4% and 6% of BioNTech. The closing of the transaction, expected in 2025, is based on the fulfillment of certain customary closing conditions and required regulatory approvals. Year to date, shares of CureVac have surged 61% against the industry's 4.8% decline. Image Source: Zacks Investment Research The acquisition of CureVac will help BioNTech enhance its capabilities in advancing investigational mRNA-based cancer immunotherapies by expanding its research, development, manufacturing and commercialization infrastructure. It complements BioNTech's existing strengths in mRNA design, delivery technologies and production. BNTX's Comirnaty is the first approved mRNA-based vaccine for COVID-19, which was developed in collaboration with Pfizer. Strategically, the deal will allow BioNTech to expand beyond its existing oncology pipeline and focus on its newer programs across several tumor types, including key assets like its mRNA-based cancer candidates and BNT327, a PD-L1xVEGF-A bispecific antibody. We remind the investors that earlier in June, BioNTech signed a strategic collaboration agreement with Bristol Myers BMY for the global co-development and co-commercialization of BNTX's BNT327, as monotherapy and in combinations, across numerous solid tumor types. BMY will pay $1.5 billion upfront, with $2 billion in additional payments through 2028 and up to $7.6 billion in milestones. BioNTech and Bristol Myers will equally share costs and profits. BNT327 is in late-stage, potentially registrational clinical studies for two different lung cancer indications. Another phase III study evaluating the candidate in triple-negative breast cancer is planned to start by the end of 2025. Early data show promising synergy in targeting two key cancer pathways. CureVac N.V. price-consensus-chart | CureVac N.V. Quote CureVac currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the biotech sector is Immunocore IMCR, currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here. In the past 60 days, loss per share estimates for Immunocore's 2025 have improved from $1.50 to 86 cents. Loss per share estimates for 2026 have narrowed from $1.68 to $1.33 during the same period. IMCR stock has gained 7.5% year to date. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report BioNTech SE Sponsored ADR (BNTX) : Free Stock Analysis Report CureVac N.V. (CVAC) : Free Stock Analysis Report Immunocore Holdings PLC Sponsored ADR (IMCR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
